Shire PLC (LON:SHP) had its price objective decreased by stock analysts at Deutsche Bank AG from GBX 5,700 ($75.22) to GBX 5,500 ($72.58) in a research report issued on Wednesday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Deutsche Bank AG’s price target would suggest a potential upside of 47.81% from the stock’s current price.
Other equities analysts also recently issued reports about the stock. Royal Bank Of Canada reissued an “outperform” rating on shares of Shire PLC in a report on Friday, July 7th. HSBC Holdings plc raised shares of Shire PLC to a “hold” rating and set a GBX 4,450 ($58.72) price target for the company in a report on Thursday, July 6th. J P Morgan Chase & Co reissued an “overweight” rating and set a GBX 6,000 ($79.18) price target on shares of Shire PLC in a report on Tuesday, July 11th. Barclays PLC reissued an “equal weight” rating and set a GBX 4,000 ($52.78) price target on shares of Shire PLC in a report on Monday. Finally, Shore Capital reissued a “buy” rating on shares of Shire PLC in a report on Wednesday, September 20th. Four research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of GBX 5,560.22 ($73.37).
Shire PLC (SHP) opened at 3721.00 on Wednesday. The firm has a 50-day moving average of GBX 3,811.88 and a 200 day moving average of GBX 4,172.02. The company’s market cap is GBX 33.73 billion. Shire PLC has a 52-week low of GBX 3,435.50 and a 52-week high of GBX 5,186.00.
ILLEGAL ACTIVITY WARNING: “Shire PLC (SHP) PT Lowered to GBX 5,500” was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.com-unik.info/2017/11/01/shire-plc-shp-pt-lowered-to-gbx-5500.html.
In other news, insider Anne Minto acquired 190 shares of the firm’s stock in a transaction that occurred on Friday, September 29th. The stock was purchased at an average price of GBX 3,785 ($49.95) per share, for a total transaction of £7,191.50 ($9,489.97). Also, insider Flemming Ornskov acquired 8,400 shares of the firm’s stock in a transaction that occurred on Tuesday, August 22nd. The shares were purchased at an average price of GBX 3,665 ($48.36) per share, with a total value of £307,860 ($406,254.95).
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
What are top analysts saying about Shire PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Shire PLC and related companies.